Piper Sandler Reiterates “Overweight” Rating for TransMedics Group (NASDAQ:TMDX)

TransMedics Group (NASDAQ:TMDX)‘s stock had its “overweight” rating reiterated by stock analysts at Piper Sandler in a note issued to investors on Wednesday,Benzinga reports. They presently have a $100.00 price objective on the stock, down from their prior price objective of $120.00. Piper Sandler’s target price would suggest a potential upside of 35.39% from the stock’s current price.

A number of other analysts have also weighed in on TMDX. Stifel Nicolaus raised their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, June 18th. Weiss Ratings downgraded shares of TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. TD Cowen reissued a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday, July 1st. Finally, UBS Group initiated coverage on TransMedics Group in a research report on Tuesday, July 28th. They set a “neutral” rating and a $80.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $124.45.

TransMedics Group Price Performance

Shares of TMDX traded down $6.89 during trading hours on Wednesday, reaching $73.86. 1,531,661 shares of the company’s stock traded hands, compared to its average volume of 1,078,920. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The stock has a market cap of $2.55 billion, a PE ratio of 16.72 and a beta of 1.90. The firm’s 50 day simple moving average is $73.01 and its 200-day simple moving average is $99.72.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter in the previous year, the business earned $0.92 EPS. The company’s revenue for the quarter was up 20.7% on a year-over-year basis. Equities analysts expect that TransMedics Group will post 1.88 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the company. Harvest Fund Management Co. Ltd purchased a new stake in shares of TransMedics Group during the third quarter worth about $29,000. North Star Investment Management Corp. bought a new position in TransMedics Group during the 1st quarter worth $30,000. Ascentis Independent Advisors acquired a new stake in TransMedics Group in the first quarter worth $30,000. Allworth Financial LP lifted its stake in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after acquiring an additional 83 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group News Roundup

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Second-quarter revenue increased 20.7% year over year to approximately $189.9 million, exceeding analyst expectations. Gross profit also rose to $113.2 million. TransMedics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: TransMedics raised its fiscal 2026 revenue outlook to $737 million-$757 million, above the roughly $733.6 million consensus estimate. This suggests continued demand for its organ-transplant technology. TransMedics Earnings Report
• Neutral Sentiment: Management’s second-quarter earnings call provided additional context on operating performance and the updated outlook, but investors remain focused on whether revenue growth can translate into renewed earnings growth. TransMedics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter adjusted earnings were approximately $0.44 per share, below the $0.50 consensus estimate and down from $0.92 a year earlier. Net income fell 57.9% year over year, while operating profit declined 35.1%, indicating significant margin pressure despite continued sales growth. TransMedics Earnings Lag Estimates
• Negative Sentiment: Operating cash flow weakened to $17.3 million, and total liabilities increased to approximately $946.3 million. Reports that company insiders have recorded sales but no purchases during the past six months may add to investor caution. TransMedics Q2 2026 Earnings News
• Negative Sentiment: Needham & Company issued a pessimistic forecast for TMDX, adding analyst-related pressure following the earnings release. Separately, Rosen Law Firm announced an investigation into potential fiduciary-duty breaches by company directors and officers, creating an additional governance overhang. Needham Pessimistic Forecast for TransMedics Rosen Law Firm Investigation

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.